ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,581 to 1,600 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Vitamins vs Placebo: Analysis of Primary Composite Outcome in Participants Randomized on or After the 13th Week of Pregnancy161 of 2,812

158 of 2,814

0.1 points

-1.1 to 1.3

5,626NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

SMARTER CRC Intervention Year 1 vs Usual Care: Abnormal FIT Results19 of 2,613

7 of 3,001

0.5 points

0.1 to 0.9

5,614NCT04890054

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC

Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) vs Arm 2: Main Cohort: Group 2: Placebo: Main Cohorts: Number of Participants With Any RT-PCR-confirmed RSV Disease13 of 2,791

43 of 2,801

-1.1 points

-1.6 to -0.6

5,592NCT03982199

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: deaths from any cause38 of 2,791

36 of 2,800

0.1 points

-0.5 to 0.7

5,591NCT03155997

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: serious adverse events344 of 2,791

202 of 2,800

5.1 points

3.6 to 6.7

5,591NCT03155997

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Conventional Axillary Dissection vs Sentinel Node Resection Followed by Node Examination: deaths from any cause0 of 2,788

1 of 2,800

-0.0 points

-0.2 to 0.1

5,588NCT00003830

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Conventional Axillary Dissection vs Sentinel Node Resection Followed by Node Examination: serious adverse events9 of 2,788

8 of 2,800

0.0 points

-0.3 to 0.4

5,588NCT00003830

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Individualized Opioid Prescription (IOPP) -Neonates/Infants vs Fixed Opioid Prescription - Neonates/Infants: Infant Hospital Readmissions59 of 2,754

63 of 2,793

-0.1 points

-0.9 to 0.7

5,547NCT04296396

Opioid Prescription After Cesarean Trial

Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.641 of 2,765

667 of 2,753

-1.0 points

-3.3 to 1.2

5,518NCT00000620

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.291 of 2,765

310 of 2,753

-0.7 points

-2.4 to 0.9

5,518NCT00000620

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Abiraterone vs Enzalutamide: deaths from any cause2,523 of 2,911

2,176 of 2,595

2.8 points

0.9 to 4.7

5,506NCT05520138

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With First Colposcopy392 of 2,741

422 of 2,738

-1.1 points

-3.0 to 0.8

5,479NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy76 of 2,740

84 of 2,737

-0.3 points

-1.2 to 0.6

5,477NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status152 of 2,740

178 of 2,737

-1.0 points

-2.2 to 0.3

5,477NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With First Colposcopy506 of 2,734

560 of 2,736

-2.0 points

-4.1 to 0.1

5,470NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status179 of 2,733

229 of 2,735

-1.8 points

-3.2 to -0.4

5,468NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide: Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy88 of 2,733

110 of 2,735

-0.8 points

-1.8 to 0.2

5,468NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Odanacatib 50 mg OW vs Placebo (Originally Assigned to Placebo): Second Extension: Number of Participants Who Experienced an Adverse Event2,173 of 3,144

1,587 of 2,309

0.4 points

-2.1 to 2.9

5,453NCT00529373

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Odanacatib 50 mg OW vs Placebo (Originally Assigned to Placebo): Second Extension: Number of Participants Discontinuing Study Treatment Due to an Adverse Event55 of 3,144

36 of 2,309

0.2 points

-0.5 to 0.9

5,453NCT00529373

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Intervention - Fall Prevention Standard of Care vs Control: deaths from any cause235 of 2,802

220 of 2,649

0.1 points

-1.4 to 1.6

5,451NCT02475850

Strategies to Reduce Injuries and Develop Confidence in Elders

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=80

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00135707-db72a3e3",
        "title": "Vitamins vs Placebo: Analysis of Primary Composite Outcome in Participants Randomized on or After the 13th Week of Pregnancy",
        "summary": "161 of 2812 against 158 of 2814; risk difference 0.1 points, 95% interval -1.1 to 1.3; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
        "record": "/library/comparisons/NCT00135707-db72a3e3",
        "nct_id": "NCT00135707",
        "kind": "outcome",
        "participants": 5626,
        "risk_difference": {
          "value": 0.0011067907768614813,
          "lower": -0.011028500087935133,
          "upper": 0.013248635880095205
        },
        "group_1": "161 of 2,812",
        "group_2": "158 of 2,814",
        "difference": "0.1 points",
        "interval": "-1.1 to 1.3",
        "trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
      },
      {
        "id": "NCT04890054-1cb05da2",
        "title": "SMARTER CRC Intervention Year 1 vs Usual Care: Abnormal FIT Results",
        "summary": "19 of 2613 against 7 of 3001; risk difference 0.5 points, 95% interval 0.1 to 0.9; NCT04890054, Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC",
        "record": "/library/comparisons/NCT04890054-1cb05da2",
        "nct_id": "NCT04890054",
        "kind": "outcome",
        "participants": 5614,
        "risk_difference": {
          "value": 0.0049387798148161615,
          "lower": 0.001341158813484039,
          "upper": 0.009171052652613065
        },
        "group_1": "19 of 2,613",
        "group_2": "7 of 3,001",
        "difference": "0.5 points",
        "interval": "0.1 to 0.9",
        "trial_title": "Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=81",
  "request_id": "Ep2Vzv4GABpZQ4HN"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?